Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial

The Lancet Oncology

Volumn 9, Issue 10, 2008, Pages 937-945

  Carozzi, Francesca ^a   Confortini, Massimo ^a   Palma, Paolo Dalla ^b   Del Mistro, Annarosa ^c   Gillio Tos, Anna ^d   De Marco, Laura ^d   Giorgi Rossi, Paolo ^e   Pontenani, Giovanni ^a   Rosso, Stefano ^d   Sani, Cristina ^a   Sintoni, Catia ^f   Segnan, Nereo ^d   Zorzi, Manuel ^c   Cuzick, Jack ^g   Rizzolo, Raffaella ^d   Ronco, Guglielmo ^d  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d Centre for Cancer Prevention   (Italy)

^e Agency for Public Health   (Italy)

^f Ravenna Hospital   (Italy)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; CANCER GRADING; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DIAGNOSIS; VIRUS INFECTION; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, MONOCLONAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 52749088718     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70208-0     Document Type: Article

References (34)

1. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone to conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100 (2008) 492-501
2. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolau screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
3. Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
4. Cuzick J., Clavel C., Petry C.-H., et al. Overview of the European and north American studies on HPV testing in primary cervical screening. Int J Cancer 119 (2006) 1095-1101
5. Khleif S.N., DeGregori J., Yee C.L., et al. Inibition of cyclin D-CDK4/CDK6 activity is associated with E2F-mediated induction of cyclin kinase inibitor activity. Proc Natl Acad Sci USA 93 (1996) 4350-4354
6. Nakao Y., Yang X., Yokoyama M., et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 75 (1997) 1410-1416
7. von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers 17 (2001) 123-128
8. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise genomic chaos created by aberrant oncogenic papillomavirus infection. Eur J Cancer 38 (2002) 2229-2242
9. Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 98 (2006) 765-774
10. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7 (2006) 547-555
11. Carozzi F., Del Mistro A., Confortini M., et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting: intralaboratory and interlaboratory quality control in seven laboratories participating in the same Clinical Trial. Am J Clin Pathol 124 (2005) 1-6
12. Luff R.D. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: a report of the 1991 Bethesda Workshop. Hum Pathol 23 (1992) 719-721
13. Carozzi F., Cecchini S., Confortini M., et al. Role of p16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer 108 (2006) 119-123
14. Dalla Palma P., Giorgi Rossi P., Collina G., et al. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histological lesions found in the NTCC trial. Am J Clin Pathol 129 (2008) 75-80
15. Schatzkin A., Connor R.J., Taylor P.R., and Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. Am J Epidemiol 125 (1987) 672-678
16. Spiegelhalter D.J., Thomas A., and Best N.G. WinBUGS version 1.2. Technical report (1999), MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
17. Klaes R., Brenner A., Friedrich T., et al. p16INK4a immunochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26 (2002) 1389-1399
18. Agoff S.N., Lin P., Morihara J., Mao C., Kiviat N.B., and Koutscky L.A. P16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 16 (2003) 665-673
19. Dray M., Russel P., Dalrymple C., et al. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 37 (2005) 112-124
20. Hu L., Guo M., He Z., Thornton J., Mc Daniel L.S., and Hughson M.D. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 18 (2005) 267-273
21. Wang S.S., Trunk M., Schiffman M., et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 (2004) 1355-1360
22. Murphy N., Ring M., Killalea A.G., et al. P16INK4A as marker for cervical diskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 56 (2003) 56-63
23. Nieh S., Chen S.F., Chu T.Y., Lai H.C., and Fu E. Expression of p16 INK4A in Papanicolau smears containing atypical cells of undetermined significance from the uterine cervix. Gynecol Oncol 91 (2003) 201-208
24. Nieh S., Chen S.F., Chu T.Y., Lai H.C., and Fu E. Expression of p16 INK4A in Papanicolau smears containing atypical glandular cells from the uterine cervix. Acta Cytol 48 (2004) 173-180
25. Guo M., Hu L., Baliga M., He Z., and Hugson M.D. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervocal intraepithelial lesions. Am J Clin Pathol 122 (2004) 894-901
26. Wenzensten N., Bergeron C., Cas F., Eschenbach D., Vinokurova S., and von Knebel Doeberitz M. Evaluation of nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer (Cancer Cytopathol) 105 (2005) 461-467
27. Holladay E.B., Logan S., Arnold J., Knesel B., and Smith G.D. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer 108 (2006) 451-461
28. INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 111 (2007) 58-66
29. INK4a assay. Cancer 111 (2007) 83-92
30. Mao C., Balasubramanian A., Yu M., et al. Evaluation of a new p16(INK4A) ELISA test and high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer 120 (2007) 2435-2438
31. Wang J.L., Zheng B.Y., Li X.D., Angstorm T., Lindstrom M.S., and Wallin K.L. Predictive value of the alterations of p16INK4A, p14ARF, p53 and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10 (2004) 2407-2414
32. Negri G., Vittadello F., Romano F., et al. p16INK4a expression and progression of low-grade intraepithelial neoplasia of the cervix. Virchows Arch 445 (2004) 616-620
33. Pretorius R.G., Zhang W.H., Belison J.L., et al. Colposcopically directed biopsy, random cervical biopsy and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 191 (2004) 430-434
34. Pretorius R.G., Bao Y.P., Belison J., Burchette R., Smith J., and Quiao Y.L. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 121 (2007) 2218-2224